Advanced Enzyme Technologies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Advanced Enzyme Technologies Limited announced its unaudited consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Consolidated revenue from operations grew ~20.3% YoY to ₹1,859.14 million from ₹1,545.24 million. Consolidated net profit rose ~15.6% YoY to ₹404.40 million from ₹349.76 million, with EPS at ₹3.57 vs ₹3.05. On a standalone basis, revenue grew ~45% YoY to ₹1,250.24 million and net profit rose to ₹739.81 million. The board also approved a ₹10 million investment in its newly incorporated wholly owned subsidiary, Advanced Nutrazyme Private Limited, which will handle nutrition and wellness product sales. The statutory auditor MSKA & Associates issued an unmodified review conclusion on both standalone and consolidated results. An interim dividend of ₹4 per share was paid during the quarter, and a final dividend of ₹1.20 per share for FY25 was approved.
Strong double-digit top-line growth on a consolidated basis signals healthy demand and expansion, though profit growth was more modest. The small subsidiary investment is routine and unlikely to move the stock. Overall, the results are constructive for shareholders with no negative auditor flags.